Insulin detemir in routine clinical practice: A 26-week follow-up in type 1 diabetic patients from the belgian predictive cohort

Acta Clinica Belgica

Volumn 64, Issue 1, 2009, Pages 49-55

  Preumont, V ^a   Buysschaert, M ^a   De Beukelaer, S ^b   Mathieu, C ^c  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Fasting blood glucose; Fasting blood glucose variability; Hypoglycaemia; PREDICTIVE; Treatment; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; ARTICLE; BELGIUM; BOLUS INJECTION; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT SATISFACTION; PREDICTION; PROSPECTIVE STUDY; SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

EID: 61349151603     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2009.009     Document Type: Article

References (20)

1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
2. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
3. DCCT Research Group. Hypoglycaemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-86.
4. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280: 140-6.
5. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352 :174-83.
6. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes 2004; 28 (suppl 2): S23-S8.
7. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycaemic control and reduced risk of hypoglycaemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-6.
8. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
9. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47 (4): 622-9.
10. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24: 296-301.
11. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27 (5): 1081-7.
12. Russel-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26 (5): 724-36.
13. Pieber T, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24 (6): 635-42.
14. Lüddeke HJ, Sreenan S, Aczel S, et al. on behalf of the PREDICTIVE Study Group. PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in type 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007; 9 (3): 428-34.
15. Dornhorst A, Luddeke HJ, Sreenan S, et al. on behalf of the PREDICTIVE study group. Safety and efficacy of insulin detemir in clinical practice: 14-weeks follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007; 61 (3): 523-8.
16. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less weight gain in patients with type 2 who were insulin naive or treated with NPH or glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Obes Metab 2007; 9 (3): 418-27.
17. Mathieu C. Can we reduce hypoglycaemia with insulin detemir? Int J Obes 2004; 28 (Suppl.2): S35-S40.
18. Summary of revisions for the 2008 clinical practice recommendations. Diabetes Care 2008; 31 (suppl 1): S3-S4.
19. Heise T, Nosek L, Biilmann Rønn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53 (6): 1614-20.
20. Fritsche A, Häring H. At last, a weight neutral insulin? Int J Obes 2004; 28 (suppl 2): S41-S6.